Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2025-05-19 Regulatory Filings
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad anuncia que su socio Adium Pharma S.A. ha recibido la aprobación para la comercialización de Zepzelca® (lurbinectedina) en Argentina.
Regulatory Filings Classification · 100% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV - Spanish Securities Market Commission) under the heading 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It announces that Pharma Mar's partner has received conditional marketing approval in Argentina for a drug (Zepzelca®). Crucially, the document explicitly states: 'Se adjunta nota de prensa que se distribuirá a los medios de comunicación en relación con esta noticia' (A press release that will be distributed to the media regarding this news is attached). The main body of the text is this attached press release. Since the primary document is a short regulatory filing announcing the publication of a press release/news item, and it is not the full financial report (10-K, IR) or the transcript (CT), it fits best as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the structure—a formal notification to the regulator followed by the attached news—RPA is the most precise fit, as it announces the release of specific news/information. The length (6187 chars) is moderate, but the content focuses on the announcement itself rather than being a comprehensive report.
2025-05-19 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled 'MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS' (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form explicitly details transactions (Compra/Buy) made by a director ('CONSEJERA') of the issuer (PHARMA MAR, S.A.). This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS.
2025-05-13 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 5 de mayo y el 9 de mayo de 2025.
Transaction in Own Shares Classification · 100% confidence The document is a formal communication to the 'Comisión Nacional del Mercado de Valores' (Spanish Securities Market Commission) dated May 12, 2025. The subject is 'Programas de recompra de acciones, estabilización y autocartera' (Share repurchase programs, stabilization, and treasury stock). It details transactions conducted under a previously announced Share Repurchase Program between May 5 and May 9, 2025. This explicitly reports on the company buying back its own shares, which directly corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS.
2025-05-12 Spanish
La Sociedad remite anuncio de convocatoria de la Junta General Ordinaria de Accionistas y propuestas de acuerdos.
AGM Information Classification · 99% confidence The document is an official announcement from PHARMA MAR, S.A. to the Comisión Nacional del Mercado de Valores (CNMV) regarding the calling of the Annual General Shareholders' Meeting ('Junta General Ordinaria de Accionistas'). It details the date, time, location, and the full 'ORDEN DEL DÍA' (Agenda), which includes items like the approval of 2024 Annual Accounts, dividend proposals, director re-election, and remuneration policy. This content directly relates to the formal procedures and materials for an AGM. The specific code for AGM-related materials, especially the formal call and agenda, is AGM-R (AGM Information). Although it mentions the accompanying documents (like Annual Accounts), the primary purpose of this filing is the convocation notice itself.
2025-05-06 Spanish
La Sociedad remite anuncio de convocatoria de la Junta General Ordinaria de Accionistas y propuestas de acuerdos.
AGM Information Classification · 99% confidence The document is an official announcement from PHARMA MAR, S.A. to the Comisión Nacional del Mercado de Valores (CNMV) regarding the calling of the Annual General Shareholders' Meeting ('Junta General Ordinaria de Accionistas'). It details the date, time, location, and the full 'ORDEN DEL DÍA' (Agenda), which includes items like the approval of 2024 Annual Accounts, dividend proposals, director re-election, and remuneration policy. This content directly relates to the formal procedures and materials for an AGM. The specific code for AGM-related materials, especially the formal call and agenda, is AGM-R (AGM Information). Although it mentions the accompanying documents (like Annual Accounts), the primary purpose of this filing is the convocation notice itself.
2025-05-06 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 28 de abril y el 2 de mayo de 2025.
Transaction in Own Shares Classification · 100% confidence The document is a formal communication to the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores) dated May 5, 2025. The subject matter is explicitly titled "Programas de recompra de acciones, estabilización y autocartera" (Share repurchase programs, stabilization, and treasury stock) and details specific 'Compra' (Buy) operations conducted by Pharma Mar, S.A. between April 28 and May 2, 2025, including volume and price. This directly corresponds to the definition of reporting the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS). Although it is a regulatory filing, POS is the more specific category than the general RNS.
2025-05-05 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.